DJSG
SRPT icon

D.J. St. Germain’s Sarepta Therapeutics SRPT Stock Holding History

D.J. St. Germain’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$305 Hold
17
– – ﹤0.01% 873
2026
Q1 		$370 Hold
17
– – ﹤0.01% 876
2025
Q4 		$366 Hold
17
– – ﹤0.01% 892
2025
Q3 		$328 Hold
17
– – ﹤0.01% 868
2025
Q2 		$291 Hold
17
– – ﹤0.01% 847
2025
Q1 		$1.08K Hold
17
– – ﹤0.01% 755
2024
Q4 		$2.07K Hold
17
– – ﹤0.01% 728
2024
Q3 		$2.12K Buy
+17
New +$2.35K ﹤0.01% 664

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

D.J. St. Germain's SRPT Position: Q2 2026 in Review

D.J. St. Germain held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 17 shares worth $305. The position accounts for ﹤0.01% of the portfolio, ranked #873.

D.J. St. Germain first reported a position in SRPT in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.12K in Q3 2024. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • D.J. St. Germain held 17 shares of Sarepta Therapeutics worth $305 as of Q2 2026.
  • D.J. St. Germain left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of D.J. St. Germain's portfolio in Q2 2026, its #873 holding.
  • D.J. St. Germain first reported a position in Sarepta Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • D.J. St. Germain's Sarepta Therapeutics position peaked at $2.12K in Q3 2024.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on D.J. St. Germain's 13F filing for Q2 2026, filed 21 Jul 2026.